Kisqali side effect skin#
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling). You may report side effects to FDA at 1-80. Call your doctor for medical advice about side effects. This is not a complete list of side effects and others may occur. Our Kisqali (ribociclib) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Because of the potential for serious adverse reactions in breastfeeding babies, breastfeeding is not recommended while taking Kisqali. It is unknown if Kisqali passes into breast milk. Kisqali is not recommended for use during pregnancy it may harm a fetus. Kisqali During Pregnancy and Breastfeeding Tell your doctor all medications and supplements you use. Kisqali may interact with ritonavir, boceprevir, clarithromycin, conivaptan, grapefruit juice, pomegranates or pomegranate juice, indinavir, azole andtifungals, lopinavir/ritonavir, nefazodone, nelfinavir, saquinavir, phenytoin, rifampin, carbamazepine, St John's wort, alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, amiodarone, disopyramide, procainamide, quinidine, and sotalol.
What Drugs, Substances, or Supplements Interact with Kisqali? The recommended starting dose of Kisqali is 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment. low levels of lymphocytes in the blood (lymphopenia),.low white blood cell count ( neutropenia, leukopenia),.Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 ( HER2)-negative advanced or metastatic breast cancer.
0 kommentar(er)
